期刊
JOURNAL OF LIPID RESEARCH
卷 54, 期 10, 页码 2800-2814出版社
ELSEVIER
DOI: 10.1194/jlr.M040618
关键词
metabolomics; neurodegeneration; sphingolipids
资金
- Dana's Angels Research Trust
- Hide and Seek Foundation for Lysosomal Disease Research
- Ara Parseghian Medical Research Foundation
- National Niemann-Pick Disease Foundation
- NIH [NCRR-02512, R01 NS-081985, NS-053677, CTSA213S, R01 NS-073661]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institutes of Health Clinical Center
Niemann-Pick type C (NPC) 1 is a rare neurodegenerative disease for which treatment options are limited. A major barrier to development of effective treatments has been the lack of validated biomarkers to monitor disease progression or serve as outcome measures in clinical trials. Using targeted metabolomics to exploit the complex lipid storage phenotype that is the hallmark of NPC1 disease, we broadly surveyed Npc1(-/-)mouse tissues and identified elevated species across multiple sphingolipid classes that increased with disease progression. There was a striking accumulation of sphingoid bases, monohexosylceramides (MCs), and GM2 gangliosides in liver, and sphingoid bases and GM2 and GM3 gangliosides in brain. These lipids were modestly decreased following miglustat treatment, but markedly decreased in response to treatment with 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD), two drugs that have shown efficacy in NPC1 animal models. Extending these studies to human subjects led to identification of sphingolipid classes that were significantly altered in the plasma of NPC1 patients. Plasma MCs and ceramides were elevated, whereas sphingoid bases were reduced in NPC1 subjects. Intervention with miglustat in NPC1 patients was accompanied by striking alterations in plasma (reductions in GM1 and GM3 gangliosides) and cerebrospinal fluid (CSF) (increased MCs) sphingolipids. Similar alterations were observed in the CSF from the NPC1 feline model following (HP-beta-CD) treatment. Our findings suggest that these lipid biomarkers may prove useful as outcome measures for monitoring efficacy of therapy in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据